Didier Plan

- Contribution to the launch of softwares intended for clinical research (Quinten, Paris) and medical imaging in oncology and cardiology (Intrasense, Paris) - Early clinical development of an innovative drug-eluting stent system in Eastern Europa (Biotronik AG, Zürich) from June to November 2009

Life-cycle management of amorolfine (Loceryl®- €90 million/year) in onychomycosis including regulatory filing (extension of indications, OTC switch and preparation of answers to the issues arisen by national agencies), due diligence, and the phase II-III clinical development of a new formulation of the product in Europe

Life-cycle management and clinical development of 3 different mapping and ablation catheter systems (RF Mesh, Mesh Mapper, and Stinger® 8mm) in cardiac arrhythmia

Clinical plan designing and involvement in three first-round venture-capital fund raising discussions for 7 different emerging companies specializing in cancer, infectious diseases and dentistry

Regulatory filing and clinical development in Europe of a new vascular protection system (EmboShield®) in patients undergoing angioplasty, which resulted in its marketing authorization approval (CE mark) and MedNova’s acquisition by Abbott

Regulatory filing, clinical development (29 trials resulting in 47 articles in peer-review journals, 240 hospitals, 25 countries, $10 million/year budget) and medical promotion of 11 different vascular stent systems and a brachytherapy system (Checkmate®)

Alignment of the clinical development of leading products to regulatory requirements and marketing objectives: Mono-Tildiem®, Dogmatil®, Tiapridal® (also: Delpral® or Tiapridex®), Xatral SR® ($130, 110, 30 and 50 million/year, respectively) in coronary artery disease and hypertension, somatization, anxiety and benign prostatic hypertrophy, respectively.

- Completion of a pivotal phase II-III study and 4 pharmacological studies on a new inhaled corticosteroid (JO1222) in asthma in Europe (10 countries) and Ontario - Regulatory filing

- Clinical development in Europe of ribosomal extracts from Candida albicans (D651) and respiratory germs (Ribomunyl® or Immucytal® - $ 30 million/year) in the prevention of vulvovaginal mycoses and lung and ENT infections, respectively; - Regulatory filing and medical promotion of Ribomunyl® in Europe

- Pharmaceutical preparation of leucocyte interferon purified to homogeneity including the setting-up of analytical and pharmacological controls - Creation and management of the “Association of European Producers of Interferon” aimed at establishing preclinical standards and identifying potential clinical indications - Creation and management of a specific legal entity aimed at developing and marketing blood cell-derived products jointly with the French Blood Centers